US Stock MarketDetailed Quotes

AMRX Amneal Pharmaceuticals

Watchlist
  • 8.890
  • +0.010+0.11%
Trading Mar 13 12:04 ET
2.76BMarket Cap-23.39P/E (TTM)

About Amneal Pharmaceuticals Company

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.

Company Profile

SymbolAMRX
Company NameAmneal Pharmaceuticals
Listing DateMay 7, 2018
Founded2002
CEOMr. Robert A. Stewart
MarketNASDAQ
Employees8100
Fiscal Year Ends12-31
Address400 Crossing Boulevard,3rd floor
CityBridgewater
ProvinceNew Jersey
CountryUnited States of America
Zip Code08807
Phone1-908-947-3120

Company Executives

  • Name
  • Position
  • Salary
  • Chirag Patel
  • Director, Co-Chief Executive Officer and President
  • 2.37M
  • Chintu Patel
  • Director and Co-Chief Executive Officer
  • 2.37M
  • Anastasios G. Konidaris
  • Principal Accounting Officer, Executive Vice President and Chief Financial Officer
  • 1.89M
  • Nikita Shah
  • Executive Vice President and Chief Human Resources Officer
  • 1.53M
  • Andrew S. Boyer
  • Executive Vice President and Chief Commercial Officer - Generics
  • 1.94M
  • Jason B. Daly
  • Senior Vice President, Chief Legal Officer and Corporate Secretary
  • 1.35M
  • Paul M. Meister
  • Chairman of the Board
  • 299.08K
  • Ted C. Nark
  • Independent Director
  • 244.70K
  • John J. Kiely, Jr
  • Independent Director
  • 284.70K
  • Emily Peterson Alva
  • Independent Director
  • 217.20K
  • Deborah M. Autor
  • Independent Director
  • 267.04K
  • Shlomo Yanai
  • Independent Director
  • 254.70K
  • J. Kevin Buchi
  • Independent Director
  • 302.20K
  • Jeffrey P. George
  • Independent Director
  • 277.20K
  • Gautam Patel
  • Independent Director
  • 217.20K
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.